Blood miR-21 and miR-26 tailor a good diagnostic model for childhood asthma

Area of Science:

• Pediatric Pulmonology
• Molecular Diagnostics
• Biomarker Research

Background:

• Childhood asthma (CAMP) is a prevalent respiratory condition with complex etiological factors.
• Identifying reliable biomarkers for asthma diagnosis and severity assessment is crucial for effective management.
• MicroRNAs (miRNAs) have emerged as potential regulators and indicators in various diseases, including asthma.

Purpose of the Study:

• To investigate the association between blood microRNA-21 (miR-21) and microRNA-26a (miR-26a) levels and the prevalence and severity of childhood asthma.
• To evaluate the diagnostic potential of miR-21 and miR-26a as biomarkers for childhood asthma.

Main Methods:

• A case-control study involving 123 children with allergic asthma (AZ) and 60 healthy controls.
• Assessment of lung function using pediatric spirometry and evaluation of asthma severity.
• Quantification of blood miR-21 and miR-26a expression levels using logistic regression analysis.
• Statistical analysis including correlation, odds ratios (OR), and area under the curve (AUC) for diagnostic potential.

Main Results:

• Children with CAMP exhibited significantly higher miR-21 expression and lower miR-26a expression compared to healthy controls.
• Asthma severity, indicated by FEV1/PV, showed a significant correlation with both miR-21 and miR-26a levels.
• Adjusted logistic regression revealed that miR-21 and miR-26a levels were significantly associated with the prevalence of allergic asthma (OR=4.180 for miR-21, OR=0.058 for miR-26a).
• Blood miR-21 and miR-26a demonstrated good diagnostic potential for childhood asthma, with AUC values of 0.85 and 0.94, respectively.

Conclusions:

• Blood miR-21 and miR-26a levels are significantly altered in children with asthma compared to healthy individuals.
• These miRNAs show strong potential as non-invasive biomarkers for the diagnosis and severity assessment of childhood asthma.
• Further research is warranted to explore the therapeutic implications of targeting these miRNA pathways in CAMP management.